©
Shutterstock
Clinical Trials
A key aim of the Department of Oncology is the optimal translation of fundamental research into patient benefit and for Oxford to become the leading centre for translational early-phase oncology trials in the UK.
Read more
Welcome to the The Department of Oncology. The Department of Oncology's mission is to improve cancer care through research and teaching. There is strong emphasis on translation, with established infrastructure to develop scientific insights toward clinical appreciation.
The Department houses over 400 staff and postgraduate students - both clinical and non-clinical - and is one of the largest departments in the University of Oxford's Medical Sciences Division. It is also home to the Institute for Radiation Oncology.
One of the key aims for the Department is to bring together basic scientific and clinical research groups from across Oxford - based in the Old Road Campus Research Building, the Radiobiology Research Institute, the Weatherall Institute for Molecular Medicine and the NHS Cancer and Haematology Centre - to apply knowledge of cancer and to develop research so that we may better understand how we can combat cancer in the most effective way possible.
MRC OXFORD INSTITUTE FOR RADIATION ONCOLOGY
The mission of the MRC Oxford Institute for Radiation Oncology is to explore aspects of radiation biology research that could yield new advances in the treatment of cancer.
DIVISION OF CANCER MEDICINE
The aims of the Division of Cancer Medicine are to understand cancer and the biological processes that govern how it starts, how it behaves and how the body responds to it.
Our News
Oxford cancer clinical trials unit receives acclaimed nursing award
13 October 2021
The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.
Anti-cancer drug derived from fungus shows promise in clinical trials
7 October 2021
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS
15 September 2021
A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.